U.S. Next Generation Sequencing Market Size To Hit USD 25.71BN By 2033
The U.S. next generation sequencing market size was estimated at USD 4.10 billion in 2023 and is projected to hit around USD 25.71 billion by 2033, growing at a CAGR of 20.15% during the forecast period from 2024 to 2033.
Key Takeaways:
U.S. Next Generation Sequencing Market Growth
The growth is attributed to factors such as advancements in technology, increasing demand for personalized medicine, and the rise in the prevalence of chronic diseases, such as cancer, and the need for early diagnosis. The increasing number of joint ventures, partnerships amongst market players, and rising investment are also expected to have a positive impact on market growth. For instance, in September 2023, Neuron23, a U.S.-based clinical-stage biotech company, partnered with QIAGEN to create a complementary diagnostic tool for Neuron23's LRRK2 inhibitor, which is intended to treat Parkinson's disease. The assay for this collaboration is integrated into an next generation sequencing (NGS) workflow that uses QIAGEN's Sample to Insight capabilities.
Government funding in the U.S. through various programs has played a significant role in boosting the NGS market. The CDC allocates funding for public health initiatives, including genomic surveillance programs. In September 2022, the American Rescue Plan allocated a sum of USD 1.7 billion to support ongoing and prospective genomic surveillance efforts. Within this funding, USD 400 million is allocated for innovation, with USD 90 million of this allocation dedicated to sustaining the Pathogen Genomics Centers of Excellence network over the subsequent five years. CDC funding supports the adoption of NGS in public health laboratories, enhancing their capacity for pathogen detection, characterization, and response.
In addition, the NIH provides substantial funding for biomedical research, including genomics and NGS-related projects. Researchers and institutions receiving NIH grants utilize NGS technologies to study various diseases, understand genetic factors, and develop personalized medicine approaches. This funding supports basic research and translational efforts, driving innovation and technology advancement in the NGS field. In 2018, the Somatic Cell Genome Editing program, initiated by the NIH, aims to eliminate obstacles restricting the clinical application of genome editing methodologies for treating diverse disorders. This initiative receives funding through the NIH Common Fund.
Furthermore, the growing prevalence of cancer in the U.S. is expected to support the NGS market growth. The American Cancer Society predicts that in the year 2024, there will be 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S. NGS is extensively utilized in oncology for tumor profiling, identifying genetic mutations, and predicting treatment responses. Cancer genomics, including the molecular characterization of tumors and the development of targeted therapies, is a major driver of the NGS market.
U.S. Next Generation Sequencing Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 4.93 Billion |
| Market Size by 2033 | USD 25.71 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 20.15% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Technology, product, application, workflow, end-use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Illumina, Inc.; QIAGEN; Thermo Fisher Scientific, Inc.; BGI; Pacific Biosciences; Bio Rad Laboratories; Oxford Nanopore Technologies, Inc.; F. Hoffmann-La Roche AG; Agilent Technologies, Inc.; Eurofins Scientific |
Segments Insights:
Technology Insights
The targeted sequencing and resequencing segment held the largest revenue share of 71.15% in 2023 and is expected to witness the fastest CAGR over the forecast period. Targeted sequencing and resequencing technologies are mainly adopted for clinical applications, such as cancer diagnostics, prenatal testing, and genetic disease screening. The ability to analyze specific genomic areas makes these technologies accurately and efficiently well-suited for clinical use, driving their widespread adoption in the healthcare industry. In addition, advances in targeted sequencing and resequencing technologies have led to increased sequencing throughput, allowing researchers to analyze larger numbers of samples simultaneously. This increased throughput enables more efficient study designs and accelerates the pace of research.
The whole genome sequencing (WGS) segment is anticipated to witness significant growth by 2033 due to the increasing adoption of precision medicine and personalized healthcare. With advancements in WGS technology, it has become possible to sequence an individual's entire genome, providing valuable insights into genetic variations and potential disease risks. This has led to the development of targeted therapies and personalized treatment plans, which can improve patient outcomes and reduce healthcare costs. Additionally, the decreasing costs of WGS and the increasing availability of sequencing services have made it more accessible to researchers and clinicians, further driving the growth of this segment.
Product Insights
The consumables segment accounted for the larger revenue share in 2023 and it is anticipated to grow at the fastest CAGR of 21.06% over the forecast period. The dominance can be attributed to the high demand for sequencing reagents, kits, and other consumables required for NGS procedures. As NGS technologies are more widely adopted in research and clinical settings, the demand for consumables is expected to continue to increase. In addition, advancements in sequencing technologies are resulting in new applications and workflows, which is further driving the demand for new and innovative consumables.
The platforms segment is expected to witness significant growth from 2024 to 2033, due to the increasing demand for better and more advanced sequencing platforms. Several companies are investing heavily in the development of new and innovative platforms that can provide faster and more accurate sequencing results. For instance, in April 2022, Thermo Fisher Scientific introduced the Ion Torrent Genexus Dx Integrated Sequencer. It is a CE-IVD marked and automated NGS platform designed to provide results within a single day. These trends are expected to continue in the coming years, driving further growth in the platform product segment.
Workflow Insights
In 2023, the sequencing segment held the largest market share of 57.63%. Sequencing workflow involves a comprehensive process of sequencing, which is critical for obtaining accurate and reliable results. It includes numerous steps, such as sample preparation, sequencing, and data analysis. The market for sequencing workflow is expected to grow further in the coming years as the demand for NGS-based research and clinical applications continues to increase.
The NGS data analysis segment is expected to grow at the highest CAGR over the forecast period, due to the increasing demand for efficient and accurate analysis of genomic data. With the growing adoption of NGS technology in various applications such as drug discovery, clinical diagnostics, and personalized medicine, the demand for NGS data analysis is expected to rise. Additionally, the availability of advanced software and tools for NGS data analysis is also contributing to the growth of this segment.
Application Insights
In 2023, the oncology segment held the largest market share of 26.69%, due to the increasing prevalence of cancer in the country. NGS technology has revolutionized cancer diagnosis and treatment by allowing for more accurate and comprehensive genomic analysis of tumors, leading to personalized and targeted therapies. Additionally, ongoing research and development in the field of oncology is driving the demand for NGS applications in this area.
The consumer genomics segment is expected to grow at the highest CAGR of 22.77% during the forecast period. There is a growing interest among consumers in learning about their genetic makeup, ancestry, and predisposition to certain health conditions. Direct-to-consumer (DTC) genetic testing companies offer affordable and convenient NGS-based DNA testing kits that provide consumers with insights into their genetic traits, ancestry, and potential health risks. This increasing consumer interest is expected to drive the demand for consumer genomics applications. Technological advancements in NGS have led to a significant reduction in the cost of sequencing, making it more accessible to consumers. As the cost of sequencing continues to decline and the efficiency of NGS platforms improves, consumer genomics companies can offer more comprehensive and affordable genetic testing services, further fueling market growth.
End-use Insights
In 2023, academic research held the largest market share of 50.59%. Academic institutions are at the forefront of genomic research and innovation. Researchers in academia are driven by interest and the purpose of knowledge, leading them to explore diverse areas of genomics using NGS technology. Their pioneering work drives the development of new sequencing methodologies, data analysis techniques, and applications, shaping the direction of the entire field. Government funding agencies, private foundations, and research grants often support academic research. These funding sources provide financial support for purchasing NGS equipment, reagents, and computational resources necessary for conducting genomic studies. The availability of funding enables academic researchers to invest in NGS technology and infrastructure, contributing to the growth of the market.
The clinical research segment is expected to grow at the highest CAGR of 22.85% from 2024 to 2033. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have approved several NGS-based tests and assays for clinical use, particularly in oncology and infectious diseases. The establishment of regulatory frameworks and guidelines for NGS-based diagnostics has increased confidence in the reliability and accuracy of genomic testing, facilitating the adoption of NGS technology in clinical research. As regulatory approvals for NGS-based tests continue to expand across different therapeutic areas, the demand for NGS in clinical research is expected to grow.
Recent Developments
Key U.S. Next Generation Sequencing Company Insights
The key players operating in the U.S. Next Generation Sequencing (NGS) market are adopting product approval to increase the reach of their products in the market and improve the availability of their products in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.
Key U.S. Next Generation Sequencing Companies:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Next Generation Sequencing market.
By Technology
By Product
By Application
By Workflow
By End-use
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Technology
1.2.2. Product
1.2.3. Application
1.2.4. Workflow
1.2.5. End-use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Decreasing costs for genetic sequencing
3.2.1.2. Development of companion diagnostics and personalized medicine
3.2.1.3. Rise in competition among prominent market entities
3.2.1.4. Rising clinical opportunity for NGS technology
3.2.2. Market Restraint Analysis
3.2.2.1. Lack of computational efficiency for data management
3.2.2.2. Challenges associated with NGS implementation
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. NGS Market: Technology Business Analysis
4.1. Segment Dashboard
4.2. U.S. NGS Market Technology Movement Analysis
4.3. U.S. NGS Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Targeted Sequencing & Resequencing
4.4.1. Targeted sequencing & resequencing market estimates and forecast, 2020 - 2033
4.4.1.1. DNA-based targeted sequencing & resequencing
4.4.1.1.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2020 - 2033
4.4.1.2. RNA-based targeted sequencing & resequencing
4.4.1.2.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2020 - 2033
4.5. Whole Genome Sequencing
4.5.1. Whole genome sequencing market estimates and forecast, 2020 - 2033
4.6. Whole Exome Sequencing
4.6.1. Whole exome sequencing market estimates and forecast, 2020 - 2033
Chapter 5. U.S. NGS Market: Product Business Analysis
5.1. Segment Dashboard
5.2. U.S. NGS Market Product Movement Analysis
5.3. U.S. NGS Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
5.4. Platforms
5.4.1. Platforms market estimates and forecast, 2020 - 2033
5.4.1.1. Sequencing
5.4.1.1.1. Sequencing platforms market estimates and forecast, 2020 - 2033
5.4.1.2. Data Analysis
5.4.1.2.1. Data analysis platforms market estimates and forecast, 2018 - 2030 (USD Million
5.5. Consumables
5.5.1. Consumables market estimates and forecast, 2020 - 2033
5.5.2. Sample Preparation
5.5.2.1. Sample preparation market estimates and forecast, 2020 - 2033
5.5.3. Target Enrichment
5.5.3.1. Target enrichment market estimates and forecast, 2020 - 2033
5.5.4. Others
5.5.4.1. Others market estimates and forecast, 2020 - 2033
Chapter 6. U.S. NGS Market: Application Business Analysis
6.1. Segment Dashboard
6.2. U.S. NGS Market Application Movement Analysis
6.3. U.S. NGS Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology market estimates and forecast, 2020 - 2033
6.4.2. Diagnostics & Screening
6.4.2.1. Diagnostics & screening market estimates and forecast, 2020 - 2033
6.4.2.2. Oncology screening
6.4.2.2.1. Oncology screening market estimates and forecast, 2020 - 2033
6.4.2.2.2. Sporadic Cancer
6.4.2.2.2.1. Sporadic cancer screening market estimates and forecast, 2020 - 2033
6.4.2.2.3. Inherited Cancer
6.4.2.2.3.1. Inherited cancer screening market estimates and forecast, 2020 - 2033
6.4.2.3. Companion diagnostics
6.4.2.3.1. Companion diagnostics market estimates and forecast, 2020 - 2033
6.4.2.4. Other diagnostics
6.4.2.4.1. Other diagnostics market estimates and forecast, 2020 - 2033
6.4.3. Research Studies
6.4.3.1. Research studies market estimates and forecast, 2020 - 2033
6.5. Clinical Investigation
6.5.1. Clinical investigation market estimates and forecast, 2020 - 2033
6.5.2. Infectious Diseases
6.5.2.1. Infectious diseases market estimates and forecast, 2020 - 2033
6.5.3. Idiopathic Diseases
6.5.3.1. Idiopathic diseases market estimates and forecast, 2020 - 2033
6.5.4. Inherited Diseases
6.5.4.1. Inherited diseases market estimates and forecast, 2020 - 2033
6.5.5. Non-Communicable/Other Diseases
6.5.5.1. Non-communicable/other diseases market estimates and forecast, 2020 - 2033
6.6. Reproductive Health
6.6.1. Reproductive health market estimates and forecast, 2020 - 2033
6.6.2. NIPT
6.6.2.1. NIPT market estimates and forecast, 2020 - 2033
6.6.2.2. Aneuploidy
6.6.2.2.1. Aneuploidy market estimates and forecast, 2020 - 2033
6.6.2.3. Microdeletions
6.6.2.3.1. Microdeletions market estimates and forecast, 2020 - 2033
6.6.3. PGT
6.6.3.1. PGT market estimates and forecast, 2020 - 2033
6.6.4. Newborn Genetic Screening
6.6.4.1. Newborn genetic screening market estimates and forecast, 2020 - 2033
6.6.5. Single Gene Analysis
6.6.5.1. Single gene analysis market estimates and forecast, 2020 - 2033
6.7. HLA Typing/Immune System Monitoring
6.7.1. HLA typing/immune system monitoring market estimates and forecast, 2020 - 2033
6.8. Metagenomics, Epidemiology & Drug Development
6.8.1. Metagenomics, epidemiology & drug development market estimates and forecast, 2020 - 2033
6.9. Agrigenomics & Forensics
6.9.1. Agrigenomics & forensics market estimates and forecast, 2020 - 2033
6.10. Consumer Genomics
6.10.1. Consumer genomics market estimates and forecast, 2020 - 2033
Chapter 7. U.S. NGS Market: Workflow Business Analysis
7.1. Segment Dashboard
7.2. U.S. NGS Market Workflow Movement Analysis
7.3. U.S. NGS Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
7.4. Pre-sequencing
7.4.1. Pre-sequencing market estimates and forecast, 2020 - 2033
7.4.2. Library Preparation
7.4.2.1. Library preparation market estimates and forecast, 2020 - 2033
7.4.2.2. NGS Library Preparation Kits
7.4.2.2.1. NGS library preparation kits market estimates and forecast, 2020 - 2033
7.4.2.3. Semi-automated Library Preparation
7.4.2.3.1. Semi-automated library preparation market estimates and forecast, 2020 - 2033
7.4.2.4. Automated Library Preparation
7.4.2.4.1. Automated library preparation market estimates and forecast, 2020 - 2033
7.4.3. Others
7.4.3.1. Others market estimates and forecast, 2020 - 2033
7.5. Sequencing
7.5.1. Sequencing market estimates and forecast, 2020 - 2033
7.6. Data Analysis
7.6.1. Data analysis market estimates and forecast, 2020 - 2033
7.6.2. NGS Primary Data Analysis
7.6.2.1. NGS primary data analysis market estimates and forecast, 2020 - 2033
7.6.3. NGS Secondary Data Analysis
7.6.3.1. NGS secondary data analysis market estimates and forecast, 2020 - 2033
7.6.4. NGS Tertiary Data Analysis
7.6.4.1. NGS tertiary data analysis market estimates and forecast, 2020 - 2033
Chapter 8. U.S. NGS Market: End-use Business Analysis
8.1. Segment Dashboard
8.2. U.S. NGS Market End-use Movement Analysis
8.3. U.S. NGS Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
8.4. Academic Research
8.4.1. Academic research market estimates and forecast, 2020 - 2033
8.5. Clinical Research
8.5.1. Clinical research market estimates and forecast, 2020 - 2033
8.6. Hospitals & Clinics
8.6.1. Hospitals & clinics market estimates and forecast, 2020 - 2033
8.7. Pharmaceutical & Biotech Entities
8.7.1. Pharmaceutical & biotech entities market estimates and forecast, 2020 - 2033
8.8. Other Users
8.8.1. Other users market estimates and forecast, 2020 - 2033
Chapter 9. Competitive Landscape
9.1. Participant Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2023
9.4. Participant’s Overview
9.4.1. Illumina
9.4.1.1. Overview
9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. QIAGEN
9.4.2.1. Overview
9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Thermo Fisher Scientific, Inc.
9.4.3.1. Overview
9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Bio-Rad Laboratories, Inc.
9.4.4.1. Overview
9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Oxford Nanopore Technologies
9.4.5.1. Overview
9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Pacific Biosciences
9.4.6.1. Overview
9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Agilent Technologies, Inc
9.4.7.1. Overview
9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. BGI
9.4.8.1. Overview
9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. F. Hoffmann-La Roche AG
9.4.9.1. Overview
9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Eurofins Scientific
9.4.10.1. Overview
9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers